Extracellular vesicles in patients in the acute phase of psychosis and after clinical improvement : an explorative study by Tunset, Mette Elise et al.
Submitted 5 May 2020
Accepted 23 July 2020











2020 Tunset et al.
Distributed under
Creative Commons CC-BY 4.0
OPEN ACCESS
Extracellular vesicles in patients in the
acute phase of psychosis and after clinical
improvement: an explorative study
Mette Elise Tunset1,2, Hanne Haslene-Hox3, Tim Van Den Bossche4,5,
Arne Einar Vaaler1,2, Einar Sulheim3,6 and Daniel Kondziella7,8
1Department of Østmarka- Division of Mental Healthcare, St. Olavs University Hospital, Trondheim, Norway
2Department of Mental Health- Faculty of Medicine and Health Sciences, Norwegian University of Science
and Technology (NTNU), Trondheim, Norway
3Department of Biotechnology and Nanomedicine, SINTEF, Trondheim, Norway
4VIB - UGent Center for Medical Biotechnology, VIB, Ghent, Belgium
5Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, Ghent,
Belgium
6Department of Physics, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
7Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
8Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark
ABSTRACT
Extracellular vesicles (EVs) are cell-derived structures that transport proteins, lipids
and nucleic acids between cells, thereby affecting the phenotype of the recipient cell. As
the content of EVs reflects the status of the originating cell, EVs can have potential as
biomarkers. Identifying EVs, including their cells of origin and their cargo, may provide
insights in the pathophysiology of psychosis. Here, we present an in-depth analysis and
proteomics of EVs from peripheral blood in patients (n= 25) during and after the acute
phase of psychosis. Concentration and protein content of EVs in psychotic patients were
twofold higher than in 25 age- and sex-matched healthy controls (p< 0.001 for both
concentration and protein content), and the diameter of EVs was larger in patients
(p= 0.02). Properties of EVs did not differ significantly in blood sampled during and
after the acute psychotic episode. Proteomic analyses on isolated EVs from individual
patients revealed 1,853 proteins, whereof 45 were brain-elevated proteins. Of these, five
proteins involved in regulation of plasticity of glutamatergic synapses were significantly
different in psychotic patients compared to controls; neurogranin (NRGN), neuron-
specific calcium-binding protein hippocalcin (HPCA), kalirin (KALRN), beta-adducin
(ADD2) and ankyrin-2 (ANK2). To summarize, our results show that peripheral EVs in
psychotic patients are different from those in healthy controls and point at alterations
on the glutamatergic system. We suggest that EVs allow investigation of blood-borne
brain-originating biological material and that their role as biomarkers in patients with
psychotic disorders is worthy of further exploration.
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INTRODUCTION
Extracellular vesicles (EVs) are nanoscale (30–1,000 nm), cell-derived, double-lipid
membrane structures containing proteins, RNAs and lipids (Van Niel, D’Angelo & Raposo,
2018; Yanez-Mo et al., 2015). They are secreted from cells by direct budding of the cell
membrane (microvesicles) or by exocytosis of multivesicular bodies (exosomes). EVs are
involved in signaling between cells and their cargo is not random but controlled by the
originating cells (Van Niel, D’Angelo & Raposo, 2018; Yanez-Mo et al., 2015). The proteins
in EVs are common to the cells of origin, which allows for identificaion of EV origin
by analyzing cell-specific proteins (Van Niel, D’Angelo & Raposo, 2018; Yanez-Mo et al.,
2015).
Evidence suggests that EVs from the brain are present in peripheral blood (Galbo Jr et
al., 2017; Goetzl et al., 2016a; Kapogiannis et al., 2019b). Hence, sampling of blood-borne
EVs may be a non-invasive way to gain access to brain-derived biological material. Since
evidence indicates that EVs are involved in brain plasticity and information storage (Chivet
et al., 2014; Fowler, 2019; Goldie et al., 2014; Pastuzyn et al., 2018; Yanez-Mo et al., 2015),
research on EVs may reveal novel insights into brain disorders in which these processes are
relevant, including psychosis. Further, psychotic disorders are associatedwith abnormalities
in several organ systems other than the brain (Pillinger et al., 2018), supporting the rational
of investigating peripheral EVs in patients with psychosis. Thus, identifying EVs, their cells
of origin and their cargomay uncover insights in the pathophysiology of psychosis andmay
serve as a source for biomarkers. In theory, EVs could also be used as therapeutic vehicles,
as evidence indicates that their membrane proteins can guide them to specific recipient cells
(Van Niel, D’Angelo & Raposo, 2018; Yanez-Mo et al., 2015). To our knowledge, there are
only four published studies on psychosis and EVs: one based on brain biopsies (Banigan et
al., 2013), a case report involving cerebrospinal fluid (CSF) analysis (Mobarrez et al., 2013),
and two studies showing altered insulin signaling in L1 cell adhesion molecule (L1CAM)
positive EVs in patients with schizophrenia (Kapogiannis et al., 2019a; Wijtenburg et al.,
2019).
In the present study, we investigated if concentration, size and protein content of EVs
differed between psychotic patients and controls, and if the state of the disease affected
these characteristics. We also explored whether brain-derived EVs could be detected in
peripheral blood, and if the pattern of brain-elevated proteins was different in patients
compared to controls. Finally, we used gene ontology (GO) analysis of the proteome to
explore which protein categories were over-represented in significantly changed proteins.
MATERIALS AND METHODS
Study participants
A total of 25 psychotic patients (six females, mean age 33.1 ± 11.0 years), during a
first episode of psychosis or during acute exacerbation of a known psychotic disorder,
were recruited between December 2016 to December 2018 from the Østmarka acute
inpatient psychiatric department, St. Olavs University Hospital, Trondheim, Norway.
Exclusion criteria were affective psychoses, heart diseases, neurological diseases, pregnancy,
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rheumatic diseases, autoimmune diseases and cancer. In addition, patients with organic
causes of psychosis were excluded. Diagnosis was assessed by ICD 10 Criteria for research
and registered after discharge from hospital. Among the 25 patients, 12 (48%) had
schizophrenia, 4 (16%) substance-induced psychotic disorder, 3 (12%) acute psychosis, 3
(12%) had unspecified psychosis and 3 (12%) had other psychotic disorders. Mean time
since onset of the first psychotic episode was 63 months± 81 months (if no earlier episode,
time since symptom debut of the present episode was registered).
A first blood sample was taken at inclusion during the acute phase of psychosis (T1). A
second blood sample was drawn 6 weeks later or more (T2), when patients were clinically
back to baseline ormuch/verymuch improved according to the Clinical Global Impression-
Improvement Scale (CGI-I). The time between sample time points was 79 ± 34 days (range:
42–162 days). The second blood sample was collected from 18 patients. Seven patients were
lost to follow-up. Ongoing abuse of recreational drugs was screened for by questioning
and a urine drug screen at first sampling time point and by questioning at second sampling
point.
Healthy control persons (n= 25) were recruited among the staff of the Department of
Psychiatry, Østmarka, St. Olavs University Hospital, Trondheim. Controls werematched to
psychotic patients according to sex and age (+/−5 years). Mean age of healthy controls was
34.2 ± 11.2 years. Exclusion criteria were the same as for the psychotic patient, including
(self-reported) illegal substance use.
Scoring range
Clinical Global Impression-Severity Scale (CGI-S) scores were registered at both sampling
points by the psychologist, board-certified psychiatrist or psychiatric resident in charge of
the patient. The CGI-S ranges from 1 (‘‘normal’’) to 7 (‘‘among the most extremely ill’’)
(Guy, 1976).
Blood sampling and EV isolation
Blood (15 ml) was collected by venipuncture in patients at the two sampling points,
and in control persons, with EDTA as anti-coagulant. The samples were kept on ice and
centrifuged fresh (2,000 g, 30 min, 4 ◦C, Hettich Rotina 420R centrifuge with rotor number
4723) within 2 h to isolate cell free plasma. Plasma (6 ml) was transferred to Eppendorf
tubes and centrifuged (10,000 g, 30 min, 4 ◦C , Eppendorf 5418R centrifuge with rotor
number FA-45-18-11). Supernatant was transferred to cryotubes, and both pellets and
supernatants were frozen at −80 ◦C awaiting further analysis. All samples were further
processed within 1 year.
Pellet fractions were thawed in room temperature and resuspended in 100 µl phosphate-
buffered saline (PBS), and pellet samples originating from the same blood sample were
pooled. The samples were centrifuged again to remove any residual cells and debris, first at
2,000 g (30min, 4 ◦C, Eppendorf 5417R with rotor number FA-45-30-11). The supernatant
was transferred to a pre-weighed Eppendorf tube and centrifuged at 10,000 g (30min, 4 ◦C).
The resulting supernatant was discarded, and the pellet was resuspended in ammonium
bicarbonate buffer (100 µl, 100 mM) for further analysis. Samples for proteomics were
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frozen at −80 ◦C in Protein LoBind Eppendorf tubes before further sample processing
(approximately 1 month). The concentration and separation approach aimed to provide an
EV sample in the high recovery, low specificity category of MISEV2018 guidelines (Thery
et al., 2018). We have submitted all relevant data of our experiments to the EV-TRACK
knowledgebase (EV-TRACK ID: EV200067) (Van Deun et al., 2017).
Characterization of isolated EV samples
The protein concentration in isolated EV samples was determined by Qubit Quant-IT
Protein Assay Kit (Thermo Fisher Scientific, cat. no. Q33211) on a Qubit Fluorometer 2.0.
EVs were analyzed for size and concentration using Nanoparticle Tracking Analysis (NTA,
Nanosight LM10, Malvern Panalytical Ltd, Malvern, UK). EVs were diluted 100-fold in
sterile PBS and three one-minute movies were recorded on the NTA (detection threshold
4, auto blur size, max jump distance).
Statistical analyses
A two-sample (un-paired) t -test was used to compare the mean values of main
characteristics of EVs (size, concentration and protein content) between the patients
in the acute phase of psychosis and healthy controls, whereas a paired sample t -test was
used to examine if main characteristics of EV changed from the acute psychotic phase (T1)
to improvement of the psychotic episode (T2). To assess if a longer history of psychosis
affected main characteristics of EVs, we compared patients with <1 year since onset of first
psychosis with patients with 1 year or more since onset of first psychosis using two-sample
t -test (un-paired). A two-sample t -test was also used to assess if drug abuse at the acute
phase changed the characteristics of EVs.
Proteomics of isolated EVs
The protein composition of EVs was determined by LC-MS/MS analysis (Choi et al., 2015).
Sample containing 30 µg of protein as determined by Qubit was diluted to 25 µL in
ammonium bicarbonate buffer (100 mM), digested by trypsin and desalted as described
earlier (Haslene-Hox et al., 2011). The sample was loaded and desalted on a pre-column
for 5 min (Acclaim PepMap 100, 2 cm × 75 µm ID nanoViper column, packed with
3 µm C18 beads, flow rate: 5 µl/min, mobile phase: 0.1% TFA). For peptide separation
a biphasic ACN gradient from two nanoflow UPLC pumps was used (flow rate of 250
nl/min, 120 min run) on a 25 cm analytical column (PepMap RSLC, 25 cm × 75 µm ID
EASY-spray column, packed with µmC18 beads with pore size 100 Å). Solvent A was 0.1%
FA (vol/vol) in water and solvent B was 100% ACN. The gradient composition was 5%B
during trapping (5 min), 5–7%B (0.5 min), 7–22%B (59.5 min), 22–35%B (22 min), and
35–90%B (5 min). To wash the column between samples, elution of very hydrophobic
peptides and conditioning of the column were performed during 10 min isocratic elution
with 80%B and 15min isocratic elution with 5%B. Peptides were ionized in the electrospray
and analyzed by an Orbitrap Q-Exactive HF. Data-dependent-acquisition (DDA) mode
was used to automatically switch between full scan MS andMS/MS acquisition. Q-Exactive
HF Tune 2.9 was used for instrument control, and XCalibur 4.1 Survey full scan MS
spectra (m/z 375-1500) were acquired with resolution R= 120,000 at m/z 200, automatic
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gain control (AGC) target of 3e6 and a maximum injection time of 100 ms. The 12 most
intense eluting peptides above an intensity threshold of 50,000 counts, and charge states 2
to 5, were sequentially isolated to a target value (AGC) of 1e5 and a maximum injection
time of 110 ms in the C-trap. Isolation width was maintained at 1.6 m/z (offset of 0.3
m/z), before fragmentation in the HCD (Higher-Energy Collision Dissociation) cell. The
minimum AGC target for fragmentation were set at 5.5e3. Normalized collision energy
(NCE) was 28% at fragmentation. Fragments were detected at a resolution of 60,000 at m/z
200, and first mass was fixed at m/z 120. One MS/MS spectrum of a precursor mass was
allowed before dynamic exclusion for 20s with ‘‘exclude isotopes’’ on. Lock-mass internal
calibration (m/z 445.12003) was enabled. Ion spray voltage was 1,800 V, no sheath and
auxiliary gas flow, and capillary temperature was 275 ◦C.
In total, 68 samples were submitted to proteomic analysis, and each sample was analysed
a single time with mass spectrometry in random order. The samples were divided in three
groups: patient samples at first time point (n= 25); patient samples at second time point
(n= 18); and control samples from age-matched healthy persons (n= 25).
Database search parameter and acceptance criteria for identification
The raw data was converted to Mascot Generic Format (mgf) peak lists with MS
convert with peak picking of MS2 to convert to centroid data (Chambers et al., 2012).
Peak lists obtained from MS/MS spectra were identified using X!Tandem (X!Tandem
Vengeance, v2015.12.15.2). The search was conducted using SearchGUI (v3.3.15). Protein
identification was conducted against a concatenated target/decoy database of Homo
sapiens (reference proteome downloaded from UniProtKB in March 2018) (Apweiler et
al., 2004) with porcine trypsin (P00761) added as possible contaminant (40,660 entries in
concatenated database, based on 20,330 entries fromuniprot.org). A reverse target sequence
decoy database was created in SearchGUI (Barsnes & Vaudel, 2018). The identification was
done with specific trypsin digest and maximum two missed cleavages. Tolerance was set
to 10 ppm for MS1 and 0.02 Da for MS2. Fixed modifications was Carbamidomethylation
of C (+57.021464 Da). Variable modification was Oxidation of M (+15.994915 Da). In
addition modifications during refinement procedure were used: Carbamidomethylation
of C (+57.021464 Da, fixed), Acetylation of protein N-term (+42.010565 Da, variable),
Pyrolidone from E (−18.010565 Da, variable), Pyrolidone from Q (−17.026549 Da,
variable), Pyrolidone from carbamidomethylated C (−17.026549 Da, variable).
PeptideShaker (v1.16.38) (Vaudel et al., 2015) was used to infer peptides and proteins
from SearchGUI spectrum identification results. Peptide Spectrum Matches (PSMs),
peptides and proteins were validated at a 1.0% False Discovery Rate (FDR) estimated using
the decoy hit distribution. Post-translational modification localizations were scored using
the D-score (Vaudel et al., 2013). All samples were processed in parallel in PeptideShaker
to provide data for all identified proteins across all samples, with individual quantitative
measures for each sample. The average precursor intensity, an average of MS1 signal for all
spectra allocated to a given protein in a given sample, was used for label-free quantitative
evaluation.
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Proteomic data analysis and submission of data to a repository
For quantification, average precursor intensities were normalized by dividing the intensity
on the sum of intensities within individual samples. Statistical analysis was performed using
Perseus (version 1.6.5.0) (Tyanova et al., 2016). Identification of significant differences in
protein detection between sample groups were analysed in Perseus, using Student’s t -test
with correction for multiple hypothesis testing by using permutation-based FDR < 0.01
and artificial within group variance s0= 0.1. Missing values were imputed from a normal
distribution with a 1.8 standard deviation shift from the average and a width of 0.3.
Gene ontology of identified proteins was analysed by PANTHER classification
system (version 15.0, released on 2020-04-07) (Mi, Muruganujan & Thomas, 2013).
The EV proteome was screened for brain-enriched proteins and membrane-proteins
as determined in the human protein atlas (The Human protein Atlas, 2018; Uhlen et al.,
2015). To control for co-isolation of lipoprotein and chylomicrons, we searched proteomic
results for apolipoproteins (Karimi et al., 2018). The mass spectrometry data along with
the identification results have been deposited to the ProteomeXchange Consortium
(Vizcaino et al., 2014) via the PRIDE partner repository (Vizcaino et al., 2016) available at
http://proteomecentral.proteomexchange.org/cgi/GetDataset with the dataset identifier
PXD016293. EV proteome will also be deposited in the Vesiclepedia (Kalra et al., 2012).
Ethics
The study was approved by the Regional Ethics committee, South East Norway (2016/949).
All participants gave their written, informed consent after a board-certified psychiatrist or
psychologist had checked that they were able to do so.
RESULTS
Clinical global impression-severity scale
The CGI-S score was used to evaluate the severeness of psychosis, and the change in state
for patients in the two sample time points. The CGI-S score showed a decline from a
median of 7 (defined as ‘‘among the most extremely ill patients’’), range 5 to 7, during
the acute psychotic period (T1) to a median of 4 (‘‘moderately ill’’), range 2-6, at T2. All
patients had a lower CGI-S score at the second time point.
Size, concentration and protein content
Mean size and concentration of EVs and protein concentration in EV fractions are shown in
Fig. 1. The protein concentration per EV was equal for all groups, and averaged at 1.2 ·10−6
± 6.7 ·10−7 µg protein/vesicles. NTA analysis showed that most vesicles in the samples
was between 75 and 200 nm in size, but larger vesicles were also present. Exosomes are
defined as vesicles 30–150 nm in size (Yanez-Mo et al., 2015), and the isolated samples are
likely a mixture of exosomes and microvesicles(the total population of vesicles is further
referred to as EVs). We found that the size, concentration and protein content of EVs from
psychotic patients differed significantly from healthy controls (Table 1A). There was no
apparent difference between T1 and T2 in the psychotic patients (Table 1B). There were no
significant differences either in EV characteristics between patients with a short (<1 year)
versus longer (≥ 1 year) history of psychosis (Table 1C).
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Figure 1 Concentration, size and protein content of EVs.Vesicle concentration (A), vesicle concentra-
tion versus size from nano-tracking analysis (B), vesicle diameter (C) and protein concentration (D) of
isolated EV fractions for psychotic patients during psychosis (T1) and in improved state (T2) and healthy




About 40% of patients with schizophrenia spectrum disorders also have a substance use
disorder (Hunt et al., 2018). Substance use disorders are highly correlated to smoking
(Smith, Mazure & McKee, 2014) and linked with poor outcomes in symptom severity and
service use in patients with psychosis (Abdel-Baki et al., 2017). We studied if a recent
intake of illegal substances affected EV parameters. Nine and 3 patients had used illegal
drugs within 1 week before T1 and T2, respectively. Within the psychosis group there was
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Table 1 Main characteristics of EVs. (A) Main characteristics of EVs in patients at first sampling point (T1) and controls. Values given as mean
(SD). (B) Main characteristics in EVs from the 18 patients with complete data at both sampling time points (T1 and T2). Values given as mean (SD).
(C) Main characteristics of EVs according to time since debut of psychosis at T1. Values given as mean (SD).





Diameter of EVs (nm) 195 (20) 180 (12) 0.002b
Concentration of EVs (particles/ml plasma) 2.4x107 (1,1x107) 1.2x107 (5.0x106) <0.001b
Protein content EVs (µg/ml plasma) 28.2(15.4) 13.3(8.9) <0.001b
Table 1B: T1 vs T2 Acute phase (T1) Improved (T2) Change 95% CI p-valuec
CGI score, median 7 4
CGI score, mean 6.5 (0.65) 3.8 (1.23)
Diameter of EVs (nm) 199 (18) 200 (25) 1 −17–13 0.798
Concentration of EVs
(particles/ml plasma)
2.2× 107 (1.0× 107) 2.3× 107 (1.3× 107) 9.5× 105 −8.6× 106–6.7× 106 0.796
Protein concentration
in EV fraction (µg/ml
plasma)
26.8(12.0) 21.4(13.1) −5.4 −5.1 –15.9 0.294
Table 1C: T1 Psychotic patients (T1, n= 25) Mean 95%CI interval p-valuea
Years since debut of psy-
chosis
<1 (n= 10) ≥ 1 (n= 15)





2.0× 107 (8.3× 106) 2.7x107(1.2× 107) −7.4× 106 −1.6× 107–1.7× 106 0.106
Diameter of EVs (nm) 193(14) 196(23) −3 −20–13 0.678
Protein concentration
in EV fraction (µg/ml
plasma)
22.4(8.5) 32.0(17.9) 9.6 −22.2–3.0 0.130
Notes.
aTwo sample t -test.
bEqual variance not assumed.
cPaired t -test.
no significant change in size of EVs in the group without illegal substance use the week
before sampling (191 nm) compared to patients with illegal substance use 1 week before
sampling (203 nm) (n= 25, mean change 12 nm, p= 0.156, equal variance not assumed)
at T1. There were no differences comparing mean concentrations in patients without (2.46
× 107 particles/ml) and with illegal substance use 1 week before sampling (2.19 × 107
particles/ml) at T1 (mean change 2.75 × 106 particles/ml n= 25, p= 0.573). There was
no significant change in mean protein content in EV fractions in patients without (28.54
µg/ml) and with illegal substance use 1 week before sampling (2.765 µg/ml) (n= 25, mean
change 0.89 µg/ml, p= 0.897).
EV proteomes
The protein cargo of EVs are central to understand their origin, function and classification
(Choi et al., 2015). Shotgun proteomics of all EV samples resulted in 1,853 identified
proteins with more than 1 identified peptide across all samples by 26,537 unique peptides,
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Figure 2 Overall proteomic findings. (A) Venn diagram showing total number of identified proteins in
psychotic patients during psychosis (T1) and in improved state (T2) and healthy controls (HC) and the
overlap between sample groups. (B) Volcano plot showing the p-value versus the fold change of all pro-
teins for all three groups compared pairwise with each other (Student’s t -test with multiple hypothesis
correction, lines showing significance threshold (Significant at p < 0.05, Artificial within groups variance
s0= 0.1)).
Full-size DOI: 10.7717/peerj.9714/fig-2
using a false positive rate (FDR) of 1% (Table S1). Of these, 1,658 (89%) proteins were
identified in all three sample groups (Hulsen, De Vlieg & Alkema, 2008). 118 proteins were
identified at one or two time points from the psychotic patient samples, while not detected
in the control group (Fig. 2A). To verify the EV origin, the proteomes were compared to
the 100 most frequent proteins found in exosomes from Exocarta (2018). We identified 93
of these in our sample material, without difference between patient samples and controls.
This includes known positive EV markers including cytosolic proteins recovered in EVs
(Alix (Q8WUM4), Tsg101 (Q99816)) and transmembrane or GPI-anchored proteins
associated to plasma membranes or endosomes (CD9 (P21926), CD81 (P60033) and
CD63 (P08962)), demonstrating that the isolated EV fractions in this study contained
EVs (Thery et al., 2018). The enrichment of the EV proteomes was also confirmed by
comparing the 1853 proteins identified with the human proteome by GO enrichment
analysis. The GO-terms extracellular exosomes and vesicle-mediated transport were among
the mostly enriched GO-terms (Table S2A), verifying that the EV isolation process yielded
an EV-enriched fraction.
Differentially expressed proteins were identified by comparing proteins in groups
pairwise by normalized average precursor intensity of identified proteins (Fig. 2B). No
proteins were identified as differentially expressed between T1 and T2, although COP9
signalosome complex subunit 6 (Q7L5N1) had significant p-value (p< 0.001) and close
to significant fold change (0.66). In T1 and T2, 119 and 40 proteins were differentially
expressed compared with healthy controls (HC), respectively (complete lists in Table S3).
Combined, 131 proteins were differently expressed in T1 and/or T2 compared with HC,
102 proteins had increased abundance in T1 and/or T2 compared with HC, while 29
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proteins had a lower abundance. The relative variance and distribution for each protein
between samples within one group was considered to evaluate different heterogeneity in
the three sample groups, and were similar for HC, T1 and T2 groups. Thus, the group
heterogeneity was similar for HC, T1 and T2.
The proteins that were differentially expressed in psychotic patients compared with
healthy controls were submitted to GO overrepresentation analysis, to identify enriched
GO terms for the changed proteins (significantly enriched GO terms compared to the
human proteome, FDR threshold at 0.05) (Tables S2B and S2C).
Proteins with higher abundance in psychotic patients had overrepresented GO-terms
related to localization and transport inside and out of the cell, as well as leukocyte and
neutrophil activation. GO terms enriched for proteins that had a higher abundance in
HC samples were represented by lipoprotein processes, the immunoglobulin complex and
complement pathway. Of note, the GO terms main axon and postsynapse were enriched
in the proteins with higher abundance in healthy controls and represented 9 proteins
(Table S4).
The mass spectrometry data along with the identification results have been deposited to
the ProteomeXchange Consortium (Vizcaino et al., 2014) via the PRIDE partner repository
(Vizcaino et al., 2016) available at http://proteomecentral.proteomexchange.org/cgi/
GetDataset with the dataset identifier PXD016293 and Project DOI 10.6019/PXD016293 .
Lipoproteins
Lipoproteins are an important constituent of EVs and occur also in plasma as lipid particles
that can co-isolate with EVs (Raposo & Stoorvogel, 2013). Sixteen apolipoproteins were
identified by proteomics, including suggested markers for non-EV co-isolated structures
(Apolipoprotein A1/2 and B). Significant differences with higher levels in healthy controls
were found for Apolipoprotein L1, B-100, A-I and A-IV (Table S5). The apolipoproteins
contributed with 1.0 to 6.0% of the total signal intensity for each sample analysed by
proteomics (average 2.3%), indicating that the overall contribution of lipoproteins in the
samples are low. The percentage contribution of apolipoprotein spectra was higher in
healthy controls (2.6 ± 1.0) compared with T1 (2.0 ± 0.9) (p= 0.04, unpaired t -test),
but not T2. The GO term for chylomicron and lipid-particle formation was enriched in
proteins more abundant in healthy controls, also corroborating that the concentration of
lipid particles in HC compared with psychotic patients is proportionally higher.
Brain proteins
The overall EV proteome is not dominated by brain elevated proteins, but include proteins
from EVs originating from blood cells, immune cells and endothelial cells in addition to
tissue-derived EVs. Proteins that can originate from the brain was identified by comparison
of our EV proteome with the list of genes with an elevated expression in the brain compared
to other tissue types in the tissue atlas of Human Protein Atlas (The Human Protein Atlas,
2018; Uhlen et al., 2015). These proteins have at least a four-fold higher mRNA level in the
brain compared to the average level in all other tissues according to The Human Protein
Atlas. We identified 45 proteins in our EV proteome (Table S6) that were also found as
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Figure 3 Total amount of brain-elevated proteins and significantly changed brain proteins. Scatter
plot for normalized (divided by total sum within each sample) average precursor intensity with mean
(bar) and standard deviation (error bars) for the five brain proteins identified as significantly different be-
tween psychotic patients during psychosis (T1) and/or in improved state (T2) and healthy controls (HC).
(A) Neurogranin (Q92686), (B) Neuron-specific calcium-binding protein hippocalcin (HPCA, P84074),
(C) Kalirin (O60229), (D) Beta-adducin (P35612), (E) Ankyrin-2 (Q01484) and (F) all 45 brain-elevated
proteins.
Full-size DOI: 10.7717/peerj.9714/fig-3
elevated in brain in the Human Protein Atlas (The Human protein Atlas, 2018; Uhlen et al.,
2015). The sum of spectral intensities for all brain elevated proteins showed no difference
between patients and controls (Fig. 3F). In addition to the tissue categories defined by
mRNA data, the Human protein atlas gives an expression summary for each protein, this
is based on UniProt protein existence; a Human Protein Atlas antibody- or RNA based
score and evidence based on PeptideAtlas (The Human Protein Atlas, 2018; Uhlen et al.,
2015). Although this summary is not given as a score we have used it to eliminate the
proteins with the lowest specificity. Five of the proteins with a high expression in the
brain based on the protein expression summary had significant different abundancies in
healthy controls compared to patients (Fig. 3, Table 2, Student’s t -test with correction for
multiple hypothesis testing by using permutation-based FDR <0.01 and artificial within
group variance s0= 0.1).
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Table 2 Significantly changed brain proteins.Overview of the five brain proteins identified as different between healthy controls (HC) and patients with psychosis (T1)
and in improved state (T2). The table shows accession number in Uniprot, molecular weight (MW), number of validated peptides and spectra across all samples, and Av-









Average precursor intensity (Mean± SD (n))
HC T1 T2




22.4 4 80 188,914± 114,734 (14) 281,593± 145,068 (21) 263,648± 145,611 (16)
O60229 Kalirin 340.0 11 106 229,014± 142,100 (9) 337,939± 176,321 (19) 330,904± 115,006 (11)
P35612 Beta-adducin 80.8 13 99 305,652± 169,514 (20) 165,875± 63,467 (3) 309,466± 201,639 (5)





Membrane-bound protein candidates for immunolabeling of
brain-derived EVs
To enable isolation of EVs from the brain, surface proteins with high specificity to the
brain can be targeted either in immunoaffinity chromatography or fluorescence activated
cell sorting (FACS). We have used the expression summary in the human protein atlas
to identify the most brain-specific surface proteins among our identified brain elevated
proteins; Plexin B3 (PLXNB3) C type lectin domain 2 family L (CLEC2L), myelin basic
protein (MBP) and potassium voltage-gated channel subfamily A member 2 (KCNA2)
(The Human Protein Atlas, 2018; Uhlen et al., 2015). We also detected purinergic receptor
P2Y12 (P2RY12), a surface protein with high expression in microglia (The Human Protein
Atlas, 2018).
DISCUSSION
We present the first characterization of blood-based EVs isolated from psychotic patients
with extensive peripheral blood EV proteomes for psychotic patients and healthy
persons (Braga-Lagache et al., 2016), contributing to the construction of a comprehensive
proteomic database for EV proteins (Choi et al., 2015). Size, concentration and protein
concentration in EVs were all increased in psychotic patients compared to controls and
remained unaltered with clinical improvement. Use of illegal substances or duration of
the psychotic disorder had no influence on EV characteristics, indicating that the findings
correlate to other factors than an unhealthy life style which is common in patients with
psychosis (Jakobsen et al., 2018). This could suggest that our findings are related to the
psychiatric condition itself rather than representing confounders.
Brain-elevated proteins derived from EVs
We identified several brain-specific and brain-elevated proteins in isolated EVs from
psychotic patients and healthy controls. Brain-specific proteins have previously been found
in EVs from patients with malignant glioma, Alzheimer’s disease (AD), frontotemporal
dementia and healthy controls (Galbo Jr et al., 2017; Goetzl et al., 2016a), indicating that
EVs originating from the brain can enter the bloodstream. The most likely route is via
the brain glymphatic system that can transport large molecules and cells (Louveau et al.,
2015). Transport via the blood–brain barrier (BBB) may also contribute this, as preclinical
evidence suggests an inflammatory dose-dependent transcytosis of EVs through the
BBB (Andras et al., 2017; Matsumoto et al., 2017). Comparing the average content of all
brain-elevated proteins, we noticed no difference between patients and controls. Although
a crude estimate, this suggest that the difference between patients and controls in terms of
total production, clearance by the glymphatics and passage of brain EVs through the BBB
is minor.
Neurogranin, neuron-specific calcium-binding protein hippocalcin,
kalirin, beta-adducin and ankyrin-2
We found 5 brain proteins with different abundances in patients and controls; all these
proteins are involved in the regulation of glutamatergic synapses. GO analysis pointed in
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the same direction as analysis of individual brain proteins; the GO terms main axon and
postsynapse had higher abundance in healthy controls. The formation of neuronal circuits
during brain development and their subsequent modification during lifetime require
plasticity at excitatory synapses, manifested by changes in synaptic strength (Hanley, 2018).
Long-term potentiation (an increase in synaptic strength) and long-term depression (a
decrease in synaptic strength) are synapse-specific forms of plasticity (Hanley, 2018). Two
important postsynaptic processes are involved in the plasticity of glutamatergic synapses:
modifications in the amount of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptors (AMPAR) and morphological alterations of dendritic spines mainly mediated
by actin filament (Bosch & Hayashi, 2012). Dendritic spines are the postsynaptic structural
correlate of excitatory synapses (Han, Cooke & Xu, 2017).
AMPAR is a glutamate receptor that mediates the majority of fast synaptic excitation
in the central nervous system. To modulate the synaptic transmission strength, AMPAR
are transported to or from synapses (Hanley, 2018). An excitatory synapse containing
N -methyl-D-aspartate receptors (NMDAR), but no AMPAR, is termed a silent synapse
because of its low activity (Han, Cooke & Xu, 2017). One of the main regulators of AMPAR
endocytosis is stimulation of NMDAR (Hanley, 2018).
Hippocalcin, a Ca2+-sensing protein, is found in the retina and the brain and is among
the proteins with the highest expression in the brain (Hanley, 2018; The Human Protein
Atlas, 2018; Uhlen et al., 2015). Hippocalcin was increased in EVs from our psychotic
patients (Fig. 3B). Hippocalcin is required for long-term depression in the synapse, and a
suggested mechanism is that hippocalcin recruits AMPAR to endocytic sites in response to
NMDAR mediated Ca2+ signals (Hanley, 2018).
Kalirin levels were also increased in EVs from patients (Fig. 3C). Kalirin expression is
enriched in the forebrain. Its most abundant isoform, kalirin-7, is localized to dendritic
spines on cortical pyramidal neurons, where it plays a key role in morphological and
functional plasticity at excitatory synapses and facilitates actin remodeling such that
overexpression increases the number of dendritic spines (Penzes & Remmers, 2012).
Kalirin-7 interacts with the protein product of,DISC1, modulating the response toNMDAR
activation (Hayashi-Takagi et al., 2010; Tropea et al., 2018). When the DISC1 protein are
disrupted it predisposes the carrier to a number of mental health disorders including
schizophrenia (Sachs et al., 2005; Thomson et al., 2016; Tropea et al., 2018). In our study,
the levels of neurogranin, beta-adducin, and ankyrin-2 were lower in EVs from psychotic
patients (Figs. 3A, 3D and 3E). The expression of beta-adducin is mainly restricted to the
brain and hematopoietic tissues (The Human protein Atlas, 2018; Uhlen et al., 2015) and
regulates dendritic spine stability through actin-based synapse formation and spectrin-
based synapse stabilization (Engmann et al., 2015). Ankyrin-2 is a member of the ankyrin
family of proteins that link the integral membrane proteins to the underlying spectrin-actin
cytoskeleton and is a key presynaptic target of casein kinase 2 to maintain synapse stability
(Bulat, Rast & Pielage, 2014). Neurogranin, a neuron-specific and postsynaptic protein,
increases synaptic strength in an activity- and NMDAR-dependent manner (Zhong et al.,
2009). Decreased neurogranin levels lead to accelerated spine elimination and impaired
recruitment of AMPAR to silent synapses (Han, Cooke & Xu, 2017).
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Our results indicate weakening of the glutamatergic synapse in psychotic patients; the
high levels of kalirin being an exception. The role of the detected synapse proteins as
well as underlying mechanisms of synaptic plasticity in general, remains little understood
(Dieterich & Kreutz, 2016). However, the literature does indicate an important function of
EVs in synapse regulation (Ashley et al., 2018; Chivet et al., 2014; Fowler, 2019; Fruhbeis et
al., 2013) as is also apparent in our study.
Glutamatergic neurotransmission and psychotic disorders
One of the main hypotheses regarding the pathophysiology of psychotic disorders is
abnormal glutamatergic neurotransmission and NMDAR hypofunction (Balu & Coyle,
2015). This is supported by the fact that psychosis typically starts during adolescence,
a period involving modification of synapses (Keshavan et al., 2014). Further, NMDAR
antagonists can produce psychotic symptoms (Balu & Coyle, 2015; Thiebes et al., 2017).
Growing genetic data supports the association between schizophrenia and glutamatergic
synapse hypofunction (Fromer et al., 2014; Kirov et al., 2012; Schizophrenia Working Group
of the Psychiatric Genomics, 2014). Two large genome wide studies have identified the
GO term ‘‘abnormal long-term potentiation’’ on their top list of gene sets enriched in
schizophrenia (Pardinas et al., 2018; Pocklington et al., 2015). Two reviews also pointed at
variants in genes belonging to the postsynaptic density at the glutamatergic synapse (Hall
et al., 2015; Soler et al., 2018). Animal models have provided possible mechanisms linking
NMDAR hypofunction to the perceptual disturbances and abnormal associative learning
in schizophrenia (Clifton, Thomas & Hall, 2018; Ranson et al., 2019). To summarize,
evidence points at dysfunction of the glutamatergic synapse as a possible mechanism
in the pathophysiology of psychosis. Our results support data suggesting glutamatergic
dysfunction in psychosis and indicate a role of EVs in disease-related synaptic regulation.
Protein candidates for immunolabeling of brain-derived EVs
Our proteomic analysis revealed presence of brain-derived EVs in the blood, in a mixture of
EVs from other tissues. The isolation of brain-derived EVs from the blood EV population
can enablemore detailed analysis on EVs originating directly from the brain. To enable such
isolation, affinity methods based on antibodies recognizing surface proteins can be applied.
Neural cell adhesion molecule 1(NCAM1), L1CAM and glutamine aspartate transporter
(SLC1A3) are proteins that have been applied for immunolabeling of brain-derived
EVs (Fiandaca et al., 2015; Goetzl et al., 2015; Goetzl et al., 2016b; Kapogiannis et al., 2015;
Kapogiannis et al., 2019b; Mustapic et al., 2017). These proteins were not detected in this
study indicating low concentrations. L1CAM and NCAM1 have a low specificity for the
brain and are thus not suited for the isolation of pure fractions of brain-derived EVs (The
Human Protein Atlas, 2018; Uhlen et al., 2015). Our study identified membrane proteins
with high brain specificity (The Human Protein Atlas, 2018). The identified proteins are
promising candidates to isolate brain-enriched fractions of EVs, representing different brain
cells and compartments. Although purinergic receptor P2Y12 also is highly expressed in
peripheral immune cells, this protein is interesting as a target protein for immunolabeling of
EVs due to its high expression inmicroglia. EVs frommicrogliawill be relevant to investigate
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in the future, as evidence suggests that microglia might contribute to neuroinflammation in
psychosis but the usefulness of PET and the translocator protein tracer to assess microglia
activation in patients with psychosis has been challenged (Kroken et al., 2018).
GO analysis
GO overrepresentation analysis of significantly changed proteins revealed that
immunoglobulin complex, complement pathway and lipoprotein particle-related proteins
were overrepresented GO terms for proteins with significantly lower abundance in patients
with psychosis. These proteins are large and abundant in human plasma (Braga-Lagache et
al., 2016). The apparent increase in these GO pathways could be caused by a proportionally
larger co-precipitation of free proteins and a lower overall EV concentration in healthy
controls. Cholesterol and lipid-soluble proteins are also present within EVs and the detected
apolipoproteins may originate from the EVs themselves (Raposo & Stoorvogel, 2013). Also,
there is increasing evidence that EVs carry complement factors as cargo and on their
surface, thereby contributing to both pro- and anti-inflammatory immune states (Karasu
et al., 2018). Of note, genetic variations in some complement genes and changed levels of
complement components are associated with psychosis (Woo et al., 2019).
GO terms overrepresented in proteins significantly higher in patient samples compared
with healthy controls were terms related to localization and transportation within and out
of the cell, as well as proteins related to activation of neutrophils and other leukocytes.
This difference may indicate more active secretion and loading of EVs in psychotic
patients. According to two recent meta-analyses, the neutrophil-to-lymphocyte ratio is
increased in patients with non-affective psychosis and schizophrenia (Karageorgiou, Milas
& Michopoulos, 2019; Mazza et al., 2019), and several studies have shown other types
of inflammation and immune alterations in psychotic patients (Karageorgiou, Milas &
Michopoulos, 2019; Kroken et al., 2018; Pillinger et al., 2018) in line with our GO analyses.
Possible mechanisms could be promotion of inflammation and immune activation by EVs
trough their regulatory role or inflammation stimulating EV secretion from immune cells
and tissues (Slomka et al., 2018).
Methodological considerations
Our study cohort consisted of acutely admitted patients with a primary diagnosis within the
psychosis spectrum. This cohort reflects the real-life setting from an acute and emergency
psychiatric treatment facility (Zealberg & Brady, 1999). Although a psychiatric cohort
as ours is thus subject to heterogeneity, there are valid arguments against categorizing
psychotic disorders into toomany different diagnostic entities (Castagnini, Munk-Jorgensen
& Bertelsen, 2016; Guloksuz & Van Os, 2018; Pries et al., 2018). Even the validity of the
distinction between a primary psychosis with comorbid drug abuse and drug-induced
psychosis has been questioned (Caton et al., 2007; Mauri et al., 2017; Wearne & Cornish,
2018; Wilson et al., 2018). From a pragmatic point of view, we therefore conclude that our
cohort was suitable for the aim of our study, i.e., investigating EVs in patients in the acute
phase of psychosis and after improvement.
Selection of anti-coagulant, concentration steps and freezing and thawing EV
samples are all steps that may affect the size or concentration of vesicles in the samples
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(Barrachina et al., 2019). We aimed to start the EV isolation with fresh samples. However,
complete EV isolation and further processing of fresh samples were not feasible in a clinical
setting. All samples were centrifuged to remove cells (2,000 g) and subsequently pellet large
EVs (at 10,000 g) before EV pellets were frozen prior to further analysis, to ensure that all
samples were treated equally. An additional centrifugation step to wash the EV samples
after freezing were done to remove the largest aggregates that may have formed due to
anti-coagulant activity or freezing and thawing, likely causing a loss of vesicles, as some
vesicles have aggregated and were removed.
The use of EDTA as anti-coagulant has been shown to stimulate platelet-derived vesicle
formation in some studies (Mullier et al., 2013). Thus, we cannot rule out that the use of
EDTA or the analysis of frozen EV samples could affect the EV size and concentration as
measured withNTA (Fig. 1). Nevertheless, studies have also shown that both anti-coagulant
and freezing had limited effect on EVs isolated from platelet poor plasma (Jamaly et al.,
2018). Furthermore, we are comparing groups of samples that have been treated identically,
to ensure that results are comparable between sample groups.
Regarding the isolation of EVs, our method is simple, and aims to provide a sample of
sufficient EVs for further analysis, with high recovery and low specificity that will contain
both small and large EVs, but excluding the smallest EVs, because ultracentrifugation
was not applied (Thery et al., 2018). As the yield of EVs from a normal-sized peripheral
blood sample is modest, our available sample volumes were not sufficient for dividing
the samples into more defined, smaller, fractions, e.g., by a density gradient separation
method. However, by comparison with Exocarta and gene ontology, we demonstrated that
the obtained samples are highly enriched in EVs, and a number of positive EV markers
were identified by proteomics. We also identified apolipoproteins and albumin, which
are common non-EV contaminant proteins from blood (Thery et al., 2018), indicating the
co-isolation also of soluble proteins or protein aggregates not originating from inside the
EVs. Preliminary experiments were also done on selected samples, to isolate smaller vesicles
from the supernatant by ultracentrifugation at 110,000 g, to evaluate if this could provide
us with additional fractions of smaller EVs in sufficient volumes. However, proteomic
analysis of such samples revealed predominately abundant plasma proteins, and none
of the expected EV protein markers that were identified in the 10,000 g fraction (data
not shown). We conclude that the isolation method used in this study yields samples
enriched with important EV protein markers and with sufficient EV amounts for in-depth
characterization of individual samples.
Strengths and limitations
Our study has limitations that should be acknowledged. First, this was an explorative
study with a small and heterogenous patient cohort. Second, we were unable to control
for weight, smoking and metabolic factors that are expected to be unequally distributed
in psychotic patients and controls. Third, our study may have been subject to selection
bias with the most paranoid and anxious patients declining consent; and finally, 28% of
patients with psychosis was lost to follow-up. On the positive side, this is the first study
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that characterizes peripheral EVs in psychosis, i.e., a novel and promising opportunity to
identify biomarkers for a major psychiatric disorder.
CONCLUSIONS
Blood-borne EVs differ substantially between patients with psychotic disorders and
healthy controls. Also, amounts of several proteins involved in the regulation of plasticity
of glutamatergic synapses were altered in the psychotic patients supporting evidence
of glutamatergic dysfunction in psychosis and indicate a role of EVs in disease-related
synaptic regulation. These should be validated and studied in more detail, to progress the
understanding of the role of these proteins in psychosis. Thus, collecting peripheral EVs
allows access to brain-originating biological material and may provide novel insights about
the underlying processes of psychotic disorders.This study also contribute towards the
construction of a comprehensive proteome database for EVs, reporting the first proteomic
data for EVs in psychosis, and providing data necessary to further elucidate the biogenesis,
cargo and pathophysiological role of EVs. We suggest that future studies investigate more
thoroughly if potential confounders as lifestyle factors, medications or high stress levels
contribute to the changed EV profile in patients with psychotic disorders. The suitability
of identified surface brain proteins as tools to isolate a ‘‘liquid brain biopsy’’ should also be
evaluated further. Eventually, if our findings on the glutamatergic proteins are confirmed
it will be highly relevant to study their mechanistic role as related to EVs.
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